|
|
- 2017
Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedemaKeywords: Berinert, hereditary angioedema, long-term prophylaxis, plasma-derived C1-inhibitor, registry, safety, efficacy, thromboembolic events, self-administration, dosing Abstract: The plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) is approved in the United States as an intravenous (IV) on-demand treatment for hereditary angioedema (HAE) attacks, and, in Europe, as on demand and short-term prophylaxis
|
